Journal of Nuclear Medicine - McMaster Experts

publication venue for

Dose-escalation Study of [225Ac]-FPI-1434 (FPI-1434) in Patients (pts) with IGF-1R Expressing Advanced Solid Tumors: Preliminary Pharmacology and Dosimetry Results 2023
Inter- and intra-reader reproducibility of 18F-rhPSMA-7.3 PET interpretation in patients with newly diagnosed prostate cancer: Results from a phase 3, prospective, multicenter study (LIGHTHOUSE) 2023
PET imaging cancer stem cells using a novel zirconium-89 labelled fully human anti-CD133 antibody 2021
Deep learning-based detection of bone lesions in Tc-99m-MDP SPECT: comparison with human observers 2020
Preliminary results of a prospective, multicenter trial assessing the impact of F-18-DCFPyL-PET/CT on the management of patients with recurrent prostate cancer. 2020
Development of a North American supply of holmium-166 microspheres for Selective Internal Radiation Therapy (SIRT) of liver malignancies 2019
Individualized dosimetry for Lu177 DOTATATE therapy - What difference does it make? 2019
The contribution of multiparametric pelvic and whole body MR to the interpretation of F-18-fluoromethylcholine(FCH) or Ga-68-HBED-CC PSMA-11 (PSMA) PET/CT in the detection of pelvic recurrence or distant metastases in patients with biochemical failure following radical prostatectomy. 2019
F-18-DCFPyL PET/CT in Castration-Resistant Prostate Cancer (CRPC): Imaging results prior to and following abiraterone or enzalutemide therapy 2018
PSMA imaging with F-18-DCFPyL: evaluation of different normalization methods for uptake measurement 2018
A novel gallium-68 labelled pteroate for visualization of folate receptor positive tumors 2017
An Approach to New Oncologic PET Agent Development 2017
Improved epileptic foci localization using joint SPECT reconstruction: Phantom and patient studies 2016
Development of a High Performance Digital Silicon Photomultiplier (dSiPM) for ToF PET Imaging 2015
Electrochemical radiolabeling of COX-2 inhibitors: potential PET agents for imaging of inflammation 2015
4D Reconstruction of dynamic studies performed using Discovery NM 530c 2014
Evaluation of refractory epilepsy in children using 3D-SSP (NEUROSTAT) and FDG-PET 2014
PET and MRI associations across a spectrum of pediatric brain tumors: A report from the Pediatric Brain Tumor Consortium (PBTC) 2014
Prognostic value of baseline evaluation of FDG and NaF PET/CT in castrate-resistant prostate cancer (CRPC): Early results from a prospective phase 1 trial 2014
A practical approach to PET/MRI: Common abdominal pathology in oncology 2013
Dose reduction in newborns and infants undergoing hepatobiliary scintigraphy 2012
Registration of MR permeability and FDG uptake in pediatric brain tumors: A report from the Pediatric Brain Tumor Consortium (PBTC) 2012
Electrochemical micro flow cell for rapid PET tracer synthesis 2011
In pediatric Hodgkin's disease, diffuse marrow uptake on staging FDG-PET correlates with B symptoms 2011
Metabolic response by FDG-PET correlates with exon11 KIT mutation in patients with mucosal or acral melanoma or melanoma arising on chronically sun damaged skin treated with imatinib in a phase II trial 2011
Superior value of [18F]6-FDOPA PET/CT in staging of neuroendocrine tumors 2010
Would a high resolution cardiac-dedicated PET system improve quantification of myocardial blood flow? 2010
A versatile synthon for tagging peptides with technetium-99m and radioiodine: Synthesis and radiolabeling of carboranylalanine 2009
D- and L-enantiomers of 2-and 6-FDOPA for melanoma imaging 2009
Dose reduction in pediatric MAG-3 renal scans 2009
Evaluation of single amino acid chelate (SAAC) derivatives for the regioselective radiolabeling of peptides with technetium-99m 2009
PET imaging standards for the Ontario Provincial Registry of Cardiac Viability Imaging with FDG PET (CADRE) 2009
Pediatric reference ranges for glomerular filtration rate determined by a single injection of Tc-99m DTPA 2009
Solid state photomultiplier (SSPM)-based PET detector with capacitively multiplexed readout and electro-optical coupling for PET/MR 2009
Synthesis and in vitro screening of uPAR-targeting peptides for SPECT imaging of aggressive tumors 2009
The role of FDG-PET in the pre-surgical evaluation of children with intractable epilepsy 2009
The role of bone scintigraphy in the evaluation of children with fever of unknown origin 2009
Uniformity of FDG uptake in pediatric brain stem gliomas predicts survival 2009
A flexible and automated solid phase synthesis strategy for the preparation of novel radiopharmaceuticals. 2003
Bifunctional single amino acid chelates (SAAC) as synthons for the solid phase synthesis of Tc(I) and Re(I) radiopharmaceuticals. 2003
Single amino acid based bifunctional chelates for labeling of biomolecules with the {M(CO)(3)}(+) core and a novel {M(X)(3)} core (M = Tc/Re). 2003
A comparison of triple energy window scatter compensation methods for Ga-67 tumour imaging. 2002
Reducing bladder artifacts in clinical pelvic SPECT images. 2002
Improved synthesis, purification and characterization of (18)F3-fluoro-L-alpha-methyl-tyrosine. 2001
Performance of the dSPECT method using radiopharmaceuticals with fast uptake and/or washout kinetics. 2001
ROC optimization study of Tc-99m cardiac SPECT reconstructions with attenuation, scatter and resolution compensation using hybrid images. 2001
Reduction of hot bladder artifact in pelvic imaging using single camera rotation dynamic SPECT (dSPECT). 2001
Simultaneous emission-transmission imaging with Ga-67 and a Tc-99m scanning line source. 2001
The application of dynamic SPECT imaging (dSPECT) to renal imaging. 2000
The effect of N-2 and CO2 on the radiochemical yield and reactivity of [F-18]F-2 produced using O-18(P,N)F-18 gas targets. 2000
Electrophilic F-18 from O-18(p,n)F-18 target: Adverse effect of oxygen and oxygen difluoride on the direct fluorination of aromatic amino acids. 1999
Females with major depresion exihit lower serotonin synthesis in temporal lobe. 1999
Kinetic parameter estimation from dynamic SPECT studies. 1998
R(+)-[C-11]SKF 82957: Synthesis and evaluation in rats as a dopamine D-1 agonist tracer for PET. 1997
Radionuclidic contaminants in positron emitting isotopes produced using high-pressure water targets. 1997
Right ventricular infarction: Prognostic value of radionuclide measurements. 1997
The use of [F-18]6-fluoro-L-m-tyrosine in clinical studies of movement disorders. 1997
The use of fluorodeoxyglucose in patients suffering from Crohn's disease. 1997
Simplified method for mapping of change in cerebral glucose utilization during physiological stimulation using graphical analysis of FDG double injection. 1996
Thorax phantom for dynamic functional SPECT imaging 1996
EVALUATION OF CEREBRAL PERFUSION IMAGING WITH TECHNETIUM-99M HM-PAO FOLLOWING CEREBRAL TRAUMA IN PATIENTS WITH ACUTE AND CHRONIC SYMPTOMATOLOGY 1988
BETA-PARTICLE DOSE POINT KERNELS 1987
THE EFFECT OF RADIOTHERAPY ON TC-99M HMPAO DISTRIBUTION IN BRAIN-TUMORS - INITIAL RESULTS 1986
Interreader and Intrareader Reproducibility of¹⁸F-Flotufolastat Image Interpretation in Patients with Newly Diagnosed or Recurrent Prostate Cancer: Data from Two Phase 3 Prospective Multicenter Studies. 65:1239-1243. 2024
Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT. 65:643-650. 2024
The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer. 64:1125-1130. 2023
Management of Differentiated Thyroid Cancer: The Standard of Care. 63:189-195. 2022
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted ¹⁸F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. 62:1430-1437. 2021
Quantitative ⁶⁸Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with ¹⁷⁷Lu-DOTATATE. 62:1406-1414. 2021
Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects. 62:1323-1329. 2021
Overview of the First NRG Oncology–National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy. 62:1133-1139. 2021
Machine Learning in Nuclear Medicine: Part 2—Neural Networks and Clinical Aspects. 62:22-29. 2021
Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy. 62:6-14. 2021
Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma. 61:1326-1330. 2020
High Availability of the α7-Nicotinic Acetylcholine Receptor in Brains of Individuals with Mild Cognitive Impairment: A Pilot Study Using ¹⁸F-ASEM PET. 61:423-426. 2020
Fifth Anniversary of SNMMI Professional Relations Fellowship.. 60:20N. 2019
The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of ¹⁸F-Fluoromethylcholine or ⁶⁸Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy. 60:1253-1258. 2019
Prospective, Multisite, International Comparison of ¹⁸F-Fluoromethylcholine PET/CT, Multiparametric MRI, and ⁶⁸Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes. 60:794-800. 2019
A Distinct Advantage to Intraarterial Delivery of ⁸⁹Zr-Bevacizumab in PET Imaging of Mice With and Without Osmotic Opening of the Blood–Brain Barrier. 60:617-622. 2019
Use of a Qualification Phantom for PET Brain Imaging in a Multicenter Consortium: A Collaboration Between the Pediatric Brain Tumor Consortium and the SNMMI Clinical Trials Network. 60:677-682. 2019
An International Survey of PET/CT Clinical Reporting. 60:478-479. 2019
Machine Learning in Nuclear Medicine: Part 1—Introduction. 60:451-458. 2019
Harmonization of U.S., European Union, and Canadian First-in-Human Regulatory Requirements for Radiopharmaceuticals: Is This Possible?. 60:158-166. 2019
Use of ¹⁸F-ASEM PET to Determine the Availability of the α7-Nicotinic Acetylcholine Receptor in Recent-Onset Psychosis. 60:241-243. 2019
¹⁸F-XTRA PET for Enhanced Imaging of the Extrathalamic α4β2 Nicotinic Acetylcholine Receptor. 59:1603-1608. 2018
Appropriate Use Criteria for ¹⁸F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease. 58:2026-2037. 2017
Correlation of ¹⁸F-FDG PET and MRI Apparent Diffusion Coefficient Histogram Metrics with Survival in Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium. 58:1264-1269. 2017
Characterization of 3-Dimensional PET Systems for Accurate Quantification of Myocardial Blood Flow. 58:103-109. 2017
Response Assessment Criteria and Their Applications in Lymphoma: Part 2. 58:13-22. 2017
SNMMI Comment on the 2016 Society of Surgical Oncology “Choosing Wisely” Recommendation on the Use of PET/CT in Colorectal Cancer. 58:11-12. 2017
The Predictive Value of Early Assessment After 1 Cycle of Induction Chemotherapy with ¹⁸F-FDG PET/CT and Diffusion-Weighted MRI for Response to Radical Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma. 57:1843-1850. 2016
Reply: Somatostatin Receptor–Targeted Radiopeptide Therapy in Patients with Progressive Unresectable Meningioma. 57:1657.2-1658. 2016
Response Assessment Criteria and Their Applications in Lymphoma: Part 1. 57:928-935. 2016
Proceedings of the Second NCI–SNMMI Workshop on Targeted Radionuclide Therapy. 56:1119-1129. 2015
Somatostatin Receptor–Targeted Radiopeptide Therapy with ⁹⁰Y-DOTATOC and ¹⁷⁷Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial. 56:171-176. 2015
¹⁸F-FDG PET and MR Imaging Associations Across a Spectrum of Pediatric Brain Tumors: A Report from the Pediatric Brain Tumor Consortium. 55:1473-1480. 2014
Implementation of Multi-Curie Production of ^99mTc by Conventional Medical Cyclotrons. 55:1017-1022. 2014
Targeted Radionuclide Therapy: Proceedings of a Joint Workshop Hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging. 55:337-348. 2014
Exploratory Evaluation of MR Permeability with ¹⁸F-FDG PET Mapping in Pediatric Brain Tumors: A Report from the Pediatric Brain Tumor Consortium. 54:1237-1243. 2013
Reporting Guidance for Oncologic ¹⁸F-FDG PET/CT Imaging. 54:756-761. 2013
Detection of Lung Dysfunction Using Ventilation and Perfusion SPECT in a Mouse Model of Chronic Cigarette Smoke Exposure. 54:616-623. 2013
Nuclear Medicine in the First Year of Life. 52:905-925. 2011
Evaluation of ¹⁸F-FDG PET and MRI Associations in Pediatric Diffuse Intrinsic Brain Stem Glioma: A Report from the Pediatric Brain Tumor Consortium. 52:188-195. 2011
A bridge not too far: linking disciplines through molecular imaging probes.. 51:1258-1268. 2010
Risks Associated with Therapeutic ¹³¹I Radiation Exposure. 49:691-693. 2008
6-l-¹⁸F-Fluorodihydroxyphenylalanine PET in Neuroendocrine Tumors: Basic Aspects and Emerging Clinical Applications. 49:573-586. 2008
Assessment of Severity of Coronary Artery Stenosis in a Canine Model Using the PET Agent 18F-Fluorobenzyl Triphenyl Phosphonium: Comparison with 99mTc-Tetrofosmin. 48:1021-1030. 2007
Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.. 48:150-157. 2007
Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.. 47:1985-1994. 2006
Characterization of uptake of the new PET imaging compound 18F-fluorobenzyl triphenyl phosphonium in dog myocardium.. 47:1359-1366. 2006
Targeted radiotherapy: is the "Holy Grail" in sight?. 47:899-900. 2006
Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells.. 47:827-836. 2006
Reducing bladder artifacts in clinical pelvic SPECT images.. 45:1309-1314. 2004
Assessment of scatter compensation strategies for (67)Ga SPECT using numerical observers and human LROC studies.. 45:802-812. 2004
Equilibration of 6-[18F]fluoro-L-m-tyrosine between plasma and erythrocytes.. 41:1636-1641. 2000
Locally increased uptake of fluorine-18-fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumors. 39:1376-1380. 1998
Simplified quantification and reproducibility studies of dopamine D2-receptor binding with iodine-123-IBF SPECT in healthy subjects.. 38:31-37. 1997
Noninvasive quantification of dopamine D2 receptors with iodine-123-IBF SPECT.. 37:513-520. 1996
High-resolution PET imaging and quantitation of pharmaceutical biodistributions in a small animal using avalanche photodiode detectors. 35:1390-1396. 1994
CORRECTION. 30:1739-1740. 1989
Beta dose point kernels for radionuclides of potential use in radioimmunotherapy.. 30:1036-1046. 1989
Metabolites of 6-[18F]fluoro-L-dopa in human blood.. 29:363-369. 1988
High yield synthesis of 6-[18F]fluoro-L-dopa.. 27:417-421. 1986
Aromatic radiofluorination with [18F]fluorine gas: 6-[18F]fluoro-L-dopa.. 25:1228-1233. 1984
Problems in the interpretation of the in vivo measurement of calcium by the argon-37 method: an investigation of inert-gas elimination in humans.. 19:54-60. 1978
Letter: Effects of tin on pertechnetate distribution.. 16:690. 1975

Journal of Nuclear Medicine Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)